Esperion Therapeutics Q2 revenue up 12%, profit beats estimates

Esperion Therapeutics

05/08/2025 11:09

Corrects headline to clarify operating profit neat estimates

Overview

Esperion Q2 2025 total revenue grows 12% yr/yr to $82.4 mln

U.S. net product revenue rises 42% yr/yr to $40.3 mln

Company achieves first quarter of operating income, beating analyst expectations

Outlook

Esperion expects sustainable profitability starting in Q1 2026

Company reiterates 2025 operating expenses of $215 mln to $235 mln

Esperion anticipates Japan market approval in H2 2025

Company expects Canada market approval in Q4 2025

Result Drivers

COMMERCIAL EXECUTION - Strong commercial execution and growing adoption of bempedoic acid therapies drove revenue growth, per CEO Sheldon Koenig

ANDA SETTLEMENTS - Reached agreements with three ANDA filers to delay generic versions of NEXLETOL until 2040

OPERATING INCOME - Achieved first quarter of operating income from ongoing business, indicating progress towards sustainable profitability by Q1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Sales
$40.27 mln
Q2 Net Income
Beat
-$4.79 mln
-$27 mln (5 Analysts)
Q2 Operating Income
Beat
$15.03 mln
-$15.80 mln (4 Analysts)
Q2 Basic EPS
-$0.02
Q2 Operating Expenses
$67.36 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $4.00, about 62.7% above its August 4 closing price of $1.49

Press Release: ID:nGNX1jsZMS

 (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)